{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:53:39Z","timestamp":1761512019867},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"Purpose<\/jats:title> To evaluate the effect of single-agent rituximab given at the standard or a prolonged schedule in patients with newly diagnosed, or refractory or relapsed mantle cell lymphoma (MCL). <\/jats:p><\/jats:sec>Patients and Methods<\/jats:title> After induction treatment with the standard schedule (375 mg\/m2<\/jats:sup> weekly \u00d7 4), patients who were responding or who had stable disease at week 12 from the start of treatment were randomly assigned to no further treatment (arm A) or prolonged rituximab administration (375 mg\/m2<\/jats:sup>) every 8 weeks for four times (arm B). <\/jats:p><\/jats:sec>Results<\/jats:title> The trial enrolled 104 patients. After induction, clinical response was 27% with 2% complete responses. Among patients with detectable t(11;14)-positive cells in blood and bone marrow at baseline, four of 20, and one of 14, respectively, became polymerase chain-reaction\u2013negative after induction. Anemia was the only adverse predictor of response in the multivariate analysis. After a median follow-up of 29 months, response rate and duration of response were not significantly different between the two schedules in 61 randomly assigned patients. Median event-free survival (EFS) was 6 months in arm A versus 12 months in arm B; the difference was not significant (P = .1). Prolonged treatment seemed to improve EFS in the subgroup of pretreated patients (5 months in arm A v 11 months in arm B; P = .04). Thirteen percent of patients in arm A and 9% in arm B presented with grade 3 to 4 hematologic toxicity. <\/jats:p><\/jats:sec>Conclusion<\/jats:title> Single-agent rituximab is active in MCL, but the addition of four single doses at 8-week intervals does not seem to significantly improve response rate, duration of response, or EFS after treatment with the standard schedule. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.164","type":"journal-article","created":{"date-parts":[[2004,12,15]],"date-time":"2004-12-15T03:08:22Z","timestamp":1103080102000},"page":"705-711","source":"Crossref","is-referenced-by-count":161,"title":["Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)"],"prefix":"10.1200","volume":"23","author":[{"given":"Michele","family":"Ghielmini","sequence":"first","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Fang Hsu","family":"Schmitz","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Cogliatti","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Waltzer","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin F.","family":"Fey","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Betticher","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Schefer","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Pichert","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Ketterer","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cerny","sequence":"additional","affiliation":[{"name":"From the Oncology Institute of Southern Switzerland, Bellinzona; Swiss Institute of Applied Cancer Research Coordinating Centre, Bern; Institute of Medical Oncology, Inselspital, University of Bern; Swiss Reference Centre for Lymphoma Pathology; Kantonsspital, Aarau; Kantonsspital St Gallen, St Gallen; Kantonsspital Luzern, Luzern; Universit\u00e4tsspital Z\u00fcrich, CHUV, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"R5","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S117"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01725.x"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"R10","unstructured":"Pocock SJ: Clinical Trials: A Practical Approach . Chichester, UK, John Wiley and Sons, pp 84,1983-86"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Hsu Schmitz SF, B\u00fcrki K, et al: The effect of rituximab on patients with follicular and mantle-cell lymphoma: Swiss Group for Clinical Research (SAKK). Ann Oncol 11:123,2000-126, (suppl 1)","DOI":"10.1093\/annonc\/11.suppl_1.S123"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Hsu Schmitz SF, Cogliatti S, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood : Prepublished online February 24, 2004:DOI 10.1182\/blood-2003-10-3411","DOI":"10.1182\/blood-2003-10-3411"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Bertoni F, Roggero E, Luscieti P, et al: Clonality assessment in blood of patients with mantle cell lymphoma. Leuk Lymphoma 32:372,1999-379,","DOI":"10.3109\/10428199909167400"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data . New York, NY, Springer-Verlag Inc, 2003, section 7.6","DOI":"10.1007\/b97377"},{"key":"R15","unstructured":"Dreyling M H., Forstpointer R. Repp R., et al: Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma - final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102: 2003 (abstr 351; suppl)"},{"key":"R16","unstructured":"Hiddemann W, Dreyling MH, Forstpointner R, et al: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102: 2003 (abstr 352; suppl)"},{"key":"R17","unstructured":"Romaguera J, Cabanillas F, Dang NH, et al: Mantle cell lymphoma (MCL): High rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-Hyper CVAD (R-HCVAD) without stem cell transplant (SCT). Blood 98: 2001 (abstr 3030; suppl)"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:40:08Z","timestamp":1653511208000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,1]]}},"alternative-id":["10.1200\/JCO.2005.04.164"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.164","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}